To treat mild and moderate Covid-19 patients, the World Health Organisation (WHO) has strongly recommended Pfizer’s ‘Paxlovid’ consists of ‘nirmatrelvir’ and ‘ritonavir’ which are manufactured by the Pfizer.
The WHO has also recommended ‘remdesivir’ - another antiviral medicine - in all Covid-19 patients regardless of disease severity, due to the totality of the evidence at that time showing little or no effect on mortality.
‘Paxlovid’ is an oral antiviral drug, a combination of nirmatrelvir and ritonavir tablets. The tablet ‘Paxlovid’ was recommended by WHO to treat Covid-19 patients at the highest risk of developing severe disease and hospitalization, such as unvaccinated, older, or immunosuppressed patients.
The WHO suggested against its use in patients at lower risk as the benefits were found to be negligible.
The organization called the tablet the “best therapeutic choice for high-risk patients to date”.
WHO recommendation is based on new data from two randomized controlled trials involving 3078 patients. From the trial, it was shown that the risk of hospitalization is reduced by 85% following this treatment.